7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Diltiazem. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine. The risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate. Tranylcypromine may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Trandolapril. Methylphenidate may decrease the antihypertensive activities of Guanfacine. Methylphenidate may increase the hypertensive activities of Halothane. Methylphenidate may decrease the antihypertensive activities of Cyclothiazide. Methylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. The metabolism of Methylphenidate can be decreased when combined with Lorcaserin. The risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Nicardipine. The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Hydroflumethiazide. The risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Metyrosine. Methylphenidate may decrease the antihypertensive activities of Candesartan. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine. The serum concentration of Warfarin can be increased when it is combined with Methylphenidate. The serum concentration of Phenprocoumon can be increased when it is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Saprisartan. The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Hydralazine. Pivhydrazine may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine. The metabolism of Methylphenidate can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine. Methylphenidate may decrease the antihypertensive activities of Torasemide. Pirlindole may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Metolazone. Phenelzine may increase the hypertensive activities of Methylphenidate. The serum concentration of Phenytoin can be increased when it is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Latanoprost. Methylphenidate may decrease the antihypertensive activities of Rescinnamine. The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate. Roxatidine acetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Isradipine. The serum concentration of Methylphenidate can be increased when it is combined with Darunavir. Methantheline can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Furazolidone may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Eprosartan. Methylphenidate may decrease the antihypertensive activities of Treprostinil. The risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Theodrenaline. The risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Lacidipine. The risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Cyclopenthiazide. Methylphenidate may decrease the antihypertensive activities of Dihydralazine. Methylphenidate may decrease the antihypertensive activities of Losartan. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine. The metabolism of Methylphenidate can be decreased when combined with Ranolazine. The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Bupranolol. The metabolism of Methylphenidate can be decreased when combined with Ritonavir. Methylphenidate may decrease the antihypertensive activities of Carvedilol. Methylphenidate may decrease the antihypertensive activities of Penbutolol. Moclobemide may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Metipranolol. Methylphenidate may decrease the antihypertensive activities of Sitaxentan. Methylphenidate may decrease the antihypertensive activities of Nilvadipine. Methylphenidate may decrease the antihypertensive activities of Unoprostone. Almasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Guanethidine. The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Propranolol. Methylphenidate may decrease the antihypertensive activities of Phentolamine. Methylphenidate may decrease the antihypertensive activities of Debrisoquin. Methylphenidate may decrease the antihypertensive activities of Niguldipine. Epinastine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Calcium Carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Naftopidil. Methylphenidate may decrease the antihypertensive activities of Vincamine. The serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Fluvoxamine. Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Deserpidine. The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Carteolol. Methylphenidate may decrease the antihypertensive activities of Celiprolol. Methylphenidate may decrease the antihypertensive activities of Enalaprilat. Procarbazine may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of BQ-123. Methylphenidate may decrease the antihypertensive activities of Benazepril. The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Mirabegron. Methylphenidate may decrease the antihypertensive activities of Quinapril. The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Nitroprusside. The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate. Methylphenidate may increase the hypertensive activities of Methoxyflurane. The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Ticrynafen. The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Bosentan. The serum concentration of Methylphenidate can be increased when it is combined with Cobicistat. Methylphenidate may decrease the antihypertensive activities of Moexipril. Methylphenidate may decrease the antihypertensive activities of Cilazapril. Methylphenidate may decrease the antihypertensive activities of Candoxatril. Caroxazone may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Bimatoprost. Ranitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline. Methylphenidate may decrease the antihypertensive activities of Ferulic acid. The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate. The serum concentration of Methylphenidate can be increased when it is combined with Abiraterone. The metabolism of Methylphenidate can be decreased when combined with Celecoxib. The risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate. Pheniprazine may increase the hypertensive activities of Methylphenidate. Minaprine may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Perospirone is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline. Methylphenidate may decrease the antihypertensive activities of Zofenopril. Safrazine may increase the hypertensive activities of Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Midostaurin. The metabolism of Methylphenidate can be decreased when combined with Dronedarone. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol. The serum concentration of Fluindione can be increased when it is combined with Methylphenidate. The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.